Citation:Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S 2004
Sieber PR, Keiller DL, Kahnoski RJ, Gallo J, McFadden S. Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. J Urol 2004 Jun;171(6 Pt 1):2272-6, quiz 2435 Available from: http://www.ncbi.nlm.nih.gov/pubmed/15126801.
Compare quality appraisals for each clinical question
- Are there differences between the different hormone therapy methods in the pattern and severity of toxicity effects for non metastatic disease?
- What is the incidence of osteoporosis and reduction in bone mineral density at 2, 5 and 10 years and what is the risk of osteoporotic bone fracture due to bilateral orchidectomy (or orchidectomy), LHRH agonist or long term androgen deficiency?